WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ELVN

Based on 5 analysts offering 12 month price targets for Enliven Therapeutics Inc

Min Forecast
$62.00+13.12%
Avg Forecast
$68.60+25.16%
Max Forecast
$80.00+45.96%

Should I buy or sell ELVN stock?

Based on 5 analysts offering ratings for Enliven Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ELVN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ELVN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their ELVN stock forecasts and price targets.

ELVN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-21
lockedlocked$00.00+00.00%2026-07-09
lockedlocked$00.00+00.00%2026-07-01
lockedlocked$00.00+00.00%2026-06-29
lockedlocked$00.00+00.00%2026-06-02

1 of 1

Forecast return on equity

Is ELVN forecast to generate an efficient return?

Company
-41.55%
Industry
87.23%
Market
176.82%
ELVN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ELVN forecast to generate an efficient return on assets?

Company
-40.53%
Industry
26.37%
ELVN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ELVN earnings per share forecast

What is ELVN's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$1.78
Avg 2 year Forecast
-$2.44
Avg 3 year Forecast
-$3.20

ELVN revenue forecast

What is ELVN's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$7.3k
Avg 3 year Forecast
$12.8k

ELVN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELVN$54.81$68.60+25.16%Strong Buy
TLX$9.89$21.33+115.70%Strong Buy
ARQT$26.86$35.00+30.31%Strong Buy
GPCR$48.04$94.67+97.06%Strong Buy
NAMS$27.79$48.00+72.72%Strong Buy
View Top Biotech Stocks

Enliven Therapeutics Stock Forecast FAQ

Is Enliven Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ELVN) stock is to Strong Buy ELVN stock.

Out of 5 analysts, 3 (60%) are recommending ELVN as a Strong Buy, 2 (40%) are recommending ELVN as a Buy, 0 (0%) are recommending ELVN as a Hold, 0 (0%) are recommending ELVN as a Sell, and 0 (0%) are recommending ELVN as a Strong Sell.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.

What is ELVN's earnings growth forecast for 2026-2028?

(NASDAQ: ELVN) Enliven Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.94%.

Enliven Therapeutics's earnings in 2026 is -$98,777,000.On average, 13 Wall Street analysts forecast ELVN's earnings for 2026 to be -$108,508,252, with the lowest ELVN earnings forecast at -$112,808,141, and the highest ELVN earnings forecast at -$94,006,784. On average, 11 Wall Street analysts forecast ELVN's earnings for 2027 to be -$148,333,996, with the lowest ELVN earnings forecast at -$173,091,857, and the highest ELVN earnings forecast at -$102,959,811.

In 2028, ELVN is forecast to generate -$194,877,556 in earnings, with the lowest earnings forecast at -$231,584,967 and the highest earnings forecast at -$126,621,383.

What is ELVN's revenue growth forecast for 2026-2028?

(NASDAQ: ELVN) Enliven Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.77%.

Enliven Therapeutics's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast ELVN's revenue for 2026 to be $0, with the lowest ELVN revenue forecast at $0, and the highest ELVN revenue forecast at $0. On average, 10 Wall Street analysts forecast ELVN's revenue for 2027 to be $443,571, with the lowest ELVN revenue forecast at $0, and the highest ELVN revenue forecast at $3,197,510.

In 2028, ELVN is forecast to generate $776,538 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,197,510.

What is ELVN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ELVN) forecast ROA is -40.53%, which is lower than the forecast US Biotechnology industry average of 26.37%.

What is ELVN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ELVN price target, the average ELVN price target is $68.60, with the highest ELVN stock price forecast at $80.00 and the lowest ELVN stock price forecast at $62.00.

On average, Wall Street analysts predict that Enliven Therapeutics's share price could reach $68.60 by Jul 21, 2027. The average Enliven Therapeutics stock price prediction forecasts a potential upside of 25.16% from the current ELVN share price of $54.81.

What is ELVN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ELVN) Enliven Therapeutics's current Earnings Per Share (EPS) is -$1.67. On average, analysts forecast that ELVN's EPS will be -$1.78 for 2026, with the lowest EPS forecast at -$1.85, and the highest EPS forecast at -$1.54. On average, analysts forecast that ELVN's EPS will be -$2.44 for 2027, with the lowest EPS forecast at -$2.84, and the highest EPS forecast at -$1.69. In 2028, ELVN's EPS is forecast to hit -$3.20 (min: -$3.80, max: -$2.08).

What is ELVN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ELVN) forecast ROE is -41.55%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.